Preventive hyperbaric oxygen therapy improves acute graft-versus-host disease by activating the Nrf2/HO-1 pathway
Authors:
Open Access
- 27 February 2025
- journal article
- clinical trial-article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1529176
Abstract
Background: Hyperbaric oxygen therapy (HBOT) has been confirmed as an effective and economical therapeutic modality for treating hemorrhagic cystitis (HC), whether induced by infection or acute graft-versus-host disease (aGVHD), in transplant recipients. However, its potential benefits in treating aGVHD remain largely unknown. This study explored the effects of HBOT on aGVHD and its underlying mechanisms.Methods: The beneficial effects of HBOT on aGVHD were investigated in a murine model. Manifestations, pathological alterations, reactive oxygen species (ROS) levels in target organs, and survival data of the recipient mice were collected. Nuclear factor erythroid-derived 2-related factor 2 (Nrf2) and its downstream enzyme heme-oxygenase 1 (HO-1) expression in mouse samples were assessed via Western blot and immunohistochemistry analyses. ML385, an Nrf2 inhibitor, was used to validate the protective role of Nrf2 in the beneficial effect of HBOT on aGVHD. Furthermore, we initiated a clinical cohort study and collected data from the patients with definite aGVHD before and after HBOT to validate the preclinical conclusions.Results: We found that HBOT alleviated aGVHD in mice, which was associated with a significantly prolonged overall survival (OS) and reduced pathological injury, whereas Nrf2 inhibition had the opposite effect. HBOT decreased ROS levels and proinflammatory cytokines, including IL-6 and TNF-α, while upregulated Nrf2 and its downstream antioxidant enzyme HO-1. In the clinical cohort study, the incidence of grades 1–3 aGVHD was significantly lower in the combination arm containing HBOT than in the HBOT-free cohort.Conclusion: Preventive HBOT can mitigate aGVHD by activating the Nrf2/HO-1 signal transduction pathway, suggesting that HBOT may be a feasible approach for both the prevention and treatment of aGVHD.Clinical trial registration: ClinicalTrials.gov, identifier NCT04502628.Keywords
Funding Information
- Natural Science Foundation of Shandong Province (ZR2020MH113)
- Key Technology Research and Development Program of Shandong Province (2019GSF108207)
- National Natural Science Foundation of China (81270598, 81473486, 81770210)
- Jinan Science and Technology Bureau (201907023)
This publication has 44 references indexed in Scilit:
- Hyperbaric oxygen for radiation cystitisThe Lancet Oncology, 2019
- Tissue-specific role of Nrf2 in the treatment of diabetic foot ulcers during hyperbaric oxygen therapyFree Radical Biology and Medicine, 2019
- Assessment of mucosal integrity by quantifying neutrophil granulocyte influx in murine models of acute intestinal injuryCellular Immunology, 2017
- Abnormalities of the Bone Marrow Immune Microenvironment in Patients with Prolonged Isolated Thrombocytopenia after Allogeneic Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2017
- Adoptively transferred donor IL-17-producing CD4+ T cells augment, but IL-17 alleviates, acute graft-versus-host diseaseCellular & Molecular Immunology, 2016
- The Use of Hyperbaric Oxygen Therapy in the Treatment of Non-healing Ulcers Secondary to Graft-versus-host DiseaseJournal of the American College of Clinical Wound Specialists, 2013
- First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow TransplantationTransplantation and Cellular Therapy, 2012
- Proteasome inhibitor clioquinol as a candidate drug in prophylaxis and treatment of acute graft-versus-host diseaseMedical Hypotheses, 2010
- Molecular mechanisms of Nrf2‐mediated antioxidant responseMolecular Carcinogenesis, 2008
- Systematic review of hyperbaric oxygen in the management of chronic woundsBritish Journal of Surgery, 2005